© Reuters. Regeneron Pharma Earnings, Income Beat in This autumn
Investing.com – Regeneron Pharma (NASDAQ:) reported on Friday fourth quarter that beat analysts’ forecasts and income that topped expectations.
Regeneron Pharma introduced earnings per share of $23.72 on income of $4.95B. Analysts polled by Investing.com anticipated EPS of $20.06 on income of $4.5B.
Regeneron Pharma shares are down 1.71% from the start of the yr, nonetheless down 9.60% from its 52 week excessive of $686.62 set on September 3, 2021. They’re outperforming the S&P 500 which is down 6.06% from the beginning of the yr.
Regeneron Pharma follows different main Healthcare sector earnings this month
Regeneron Pharma’s report follows an earnings beat by UnitedHealth on January 19, who reported EPS of $4.48 on income of $73.74B, in comparison with forecasts EPS of $4.3 on income of $72.98B.
J&J had beat expectations on January 25 with fourth quarter EPS of $2.13 on income of $24.8B, in comparison with forecast for EPS of $2.12 on income of $25.28B.
Keep up-to-date on the entire upcoming earnings reviews by visiting Investing.com’s earnings calendar
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm on account of reliance on the knowledge together with information, quotes, charts and purchase/promote indicators contained inside this web site. Please be totally knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding kinds attainable.
